News Page
Published March 3, 2025
Neumora shocked investors and analysts when it announced its antidepressant navacaprant flopped in clinical trials. Shocked investors quickly sold off their shares, and Neumora’s stock price tumbled. Some investors filed a class-action against the Company to recover their losses.
Neurmora conducted an IPO in September 2023. At that time, the Company was conducting Phase 2 trials on navacaprant, a investigatory anti-depressant drug. The lawsuit says the Phase 2 trials had major issues, such as being too small and being poorly designed to control for gender.
In January 2025, Neumora revealed navacaprant failed the Phase 3 trial. Analysts were shocked and called the failure a “worst case scenario.” Analysts noted the severe design issues and said the study failure might have been prevented from the start, if the study had been designed properly.
Since the IPO, Neumora’s stock price has fallen 88.7%. Some Neumora investors are now joining the class action lawsuit.